Recognition follows a successful 2019, with Rimidi receiving multiple industry nods, announcing new partnerships and expanding its platform.
Rimidi, a cloud-based software platform that enables personalized management of chronic cardiometabolic conditions across populations, today announced its founder and chief health innovator, Lucienne Ide, MD, PhD, has been named one of HIMSS’ Most Influential Women in Health IT. Established in 2016, the award recognizes influential women who harness the power of information and technology to transform health and healthcare. All winners will be recognized during this year’s HIMSS Global Health Conference and Exhibition in Orlando, Florida from March 9 – 13.
“I am honored to be recognized by HIMSS alongside this influential group of women in health IT,” said Dr. Ide. “I left clinical practice and stepped into the world of healthcare entrepreneurship because I knew our industry could do better. Understanding the power of technology and the clinician experience, I founded Rimidi with a vision to improve patient outcomes and approval, bolster provider satisfaction, and provide clinicians with better IT, enabling them to lower costs. Today, it’s rewarding to see the true impact we’ve made by advocating for better use of data and technology.”
The HIMSS recognition follows a momentous year for Rimidi, with 2019 milestones including:
An expanded platform. Last year, Rimidi added two new views to its platform –cardiovascular disease and obesity, joining its views for diabetes, heart disease and nonalcoholic fatty liver disease. These new views prove the scalability and flexibility of the platform to support clinical workflows across various service lines and disease states.
Three award recognitions, including being named a finalist for UCSF’s Digital Health Award for Best EHR in Patient Engagement; acknowledgement by Fierce Healthcare in the 2019 Fierce Innovation Awards – Healthcare Edition; and winning the Best of Atlanta Award in the Computer Software category.
A unique partnership with Companion Medical, which brings insulin dosing data into the clinical workflow to the point of care, aiding in clinical decision making and patient engagement at Desert Oasis Healthcare (DOHC).
“As we embark on a new decade, we’re excited for the opportunities that lie ahead for our industry,” said Josh Claman, CEO of Rimidi. “At Rimidi, we’re dedicated to empowering physicians with the tools and technology they need to deliver better care, and we’ll continue to push for new approaches to care to better meet clinician and patient needs in 2020 and beyond.”
For more company news and updates, visit http://www.rimidi.com and stop by booth #1213 in The Georgia Pavilion during the week of March 9 at HIMSS 2020 in Orlando.
Recent News & Insights
Rimidi and Emory announced a collaboration to develop SMART on FHIR apps across a variety of …
New report from Rimidi and Desert Oasis Healthcare reveals the benefits of remote patient …